FOR
IMDX

Family Office Research’s Insight Molecular Diagnostics IMDX Stock Holding History

Family Office Research’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$417K Buy
+127,266
New +$739K 0.18% 51

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Family Office Research's IMDX Position: Q1 2026 in Review

Family Office Research opened a new position in Insight Molecular Diagnostics (IMDX) in Q1 2026: 127,266 shares worth $417K. The stake represents 0.18% of the portfolio and ranks #51 among its holdings.

41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Family Office Research held 127,266 shares of Insight Molecular Diagnostics worth $417K as of Q1 2026.
  • Insight Molecular Diagnostics was a new Family Office Research position in Q1 2026.
  • Insight Molecular Diagnostics made up 0.18% of Family Office Research's portfolio in Q1 2026, its #51 holding.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Family Office Research's 13F filing for Q1 2026, filed 13 May 2026.